Poolbeg Pharma PLC (POLB)

ORD 0.02P

Sell: 7.60p|Buy: 7.80p|Change: 0 (0%)

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

This investment is listed on the Alternative Investment Market (AIM). Investments on this market can be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks of investing.

Company profile

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressingcritical unmet medical needs.

Address

42 New Road
Queen Mary BioEnterprises Innovation Centre
London
GBR
E1 2AX

Telephone

+44 2071831499

Website

https://www.poolbegpharma.com

Sector

Healthcare

Forecast key dates

Name	Key Date
Poolbeg Pharma PLC Annual General Meeting for 2026	2027-06-09T11:00:00
Poolbeg Pharma PLC Annual Report for 2026	2027-05-07T00:00:00
Poolbeg Pharma PLC Fourth Quarter Earnings Results for 2026	2027-04-28T00:00:00
Poolbeg Pharma PLC Second Quarter Earnings Results for 2026	2026-09-29T00:00:00
Poolbeg Pharma PLC Annual General Meeting for 2025	2026-06-09T11:00:00

Previous key dates

Name	Key Date
Poolbeg Pharma PLC Annual General Meeting for 2025	2026-06-09T11:00:00
Poolbeg Pharma PLC Annual Report for 2025	2026-05-07T00:00:00
Poolbeg Pharma PLC Fourth Quarter Earnings Results for 2025	2026-04-28T00:00:00
Poolbeg Pharma PLC Second Quarter Earnings Results for 2025	2025-09-29T00:00:00
Poolbeg Pharma PLC Annual General Meeting for 2024	2025-06-23T12:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.